Insights | Larka

The Drug Modality and Therapeutic Area Trends of 2024.

17 October 2024 - From the perennial favourites like oncology to the booming fields of ADC and GLP-1, our latest report explores Big Pharma’s favourite drug modalities and therapeutic areas for M&A.

Report

Top 10 Pharma Companies: M&A Trends and Outlook for 2024

11 June 2024 - With revenue challenges lying ahead and plenty of cash available, Pharma top 10 is expected to increasingly turn towards M&A to secure growth in the future.

Report

8 Criteria VCs Evaluate Before Funding Biotech in 2024

15 May 2024 - Based on our survey with 50+ prominent Venture Capitalists, we have identified 8 criteria that shape how biopharma-focused VCs evaluate potential Biotech funding in 2024.

Survey

Organ-on-a-chip: Thumb-sized Organs, Huge Potential For Pharma R&D

25 January 2024 - Discover what impact organ-on-a-chip could have on drug development and how Pharma stakeholders are investing to realise its true potential.

Article

Circular RNA: Could RNA Rings Become Pharma’s New Jewel?

13 November 2023 - Pharma is betting big on circular RNA to be the next generation of therapies. Here is, in a nutshell, why you should keep an eye on this exciting technology.